On Friday, the FDA handed Lantheus Holdings Inc. (LNTH) a Complete Response Letter for its New Drug Application for LNTH-2501 — a PET diagnostic imaging kit for neuroendocrine tumors. But before you hit the panic button, here's the key detail: the FDA's issue isn't with the drug itself. It's with the third-party facility that manufactures it.

The agency cited unresolved conditions related to the facility's manufacturing processes. No concerns about the data Lantheus submitted, no red flags on safety or efficacy. Just a manufacturing paperwork snag that needs to be sorted out before the NDA can get the green light.

This isn't entirely out of the blue. Back in March, the FDA extended the PDUFA date for LNTH-2501 by three months to June 29, 2026, specifically to review manufacturing-related information. The agency noted then that the extension was standard and unrelated to the drug's performance. So the CRL is more of a continuation of that review than a surprise.

William Blair analyst Andy Hsieh summed it up nicely on Monday: "While we are disappointed by the setback, we are encouraged that the complete response letter (CRL) does not appear to be clinical in nature." In other words, the drug itself looks fine; it's the factory that needs a tune-up.

Hsieh also adjusted his model for Octevy, another PET imaging agent for neuroendocrine tumors that Lantheus has in its pipeline. He pushed the initial sales forecast back by one year, now expecting the first sales in Q1 2028 instead of Q1 2027. That's a delay, but not a derailment.

Stepping back, Hsieh sees a bigger picture that's actually pretty encouraging. Lantheus is navigating through some tricky pricing dynamics right now, but it's also preparing to transition the market to Pylarify TruVu by the end of the year. Meanwhile, the ongoing launch of Neuraceq — combined with the anticipated approval of MK-6240, a tau-directed diagnostic PET agent for Alzheimer's disease — gives the company multiple levers to pull for top-line growth.

So while the CRL is a near-term hiccup, the longer-term story remains intact. Lantheus shares were down just 0.50% on Monday, trading at $109.25, not far from their 52-week high of $111.46. Investors seem to be taking the news in stride, recognizing that this is a manufacturing issue, not a drug failure.